Laboratorios Farmaceuticos Rovi (ROVI) AI Stock Analysis

• Market Cap: €2.78B
• Dividend Yield: 1.63%
• Average Volume (3M): 99.39K
• Price to Earnings (P/E): 20.1
• Beta (1Y): 0.48
• Revenue Growth: -1.49%
• EPS Growth: 4.04%
• Country: ES
• Employees: 2,197
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): 0.35
• Shares Outstanding: 51,235,764
• 10 Day Avg. Volume: 105,315
• 30 Day Avg. Volume: 99,387
• PEG Ratio: 0.33
• Price to Book (P/B): 4.18
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -27.16
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €90.00
• Price Target Upside: 64.38% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 72 Outperform
• Price Target: €60.00 ▲(9.59%Upside)

Laboratorios Farmaceuticos Rovi scores well due to its strong financial performance, characterized by robust margins and a healthy balance sheet. Technical indicators present a mixed picture, with neutral momentum and slight short-term weakness. Valuation metrics suggest the stock is fairly valued, with the dividend yield providing additional appeal.

Laboratorios Farmaceuticos Rovi Business Overview & Revenue Model

Company Description

Laboratorios Farmaceuticos Rovi (ROVI) is a Spanish pharmaceutical company specializing in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company operates in various sectors within the pharmaceutical industry, focusing on both proprietary pharmaceutical products and contract manufacturing services. ROVI is particularly known for its expertise in the field of low molecular weight heparins and sustained-release injectables.

How the Company Makes Money

ROVI generates revenue through multiple streams, primarily from the sale of its proprietary pharmaceutical products and from offering contract manufacturing services to other pharmaceutical companies. The company's proprietary products include a range of specialty pharmaceuticals, with a significant portion of revenue derived from its low molecular weight heparins, such as Bemiparin. Additionally, ROVI acts as a contract development and manufacturing organization (CDMO), providing services that include drug formulation, manufacturing, and packaging for third-party clients. Strategic partnerships, such as licensing agreements and collaborations with other pharmaceutical companies, also play a crucial role in ROVI's revenue model, allowing the company to expand its market reach and product offerings.

Laboratorios Farmaceuticos Rovi Financial Statement Overview

Summary

Laboratorios Farmaceuticos Rovi shows a solid financial foundation with strong profitability and a stable balance sheet. While recent revenue growth has been challenging, the company maintains operational efficiency and financial stability. Continued focus on cash flow management will be key to sustaining growth and supporting strategic initiatives.

Income Statement

Laboratorios Farmaceuticos Rovi exhibits strong profitability metrics with a consistent high gross profit margin and net profit margin over the years. However, recent revenue growth has slowed, with a slight decline in the most recent year. EBIT and EBITDA margins remain robust, indicating operational efficiency despite the revenue dip.

Balance Sheet

The company maintains a healthy balance sheet with a favorable debt-to-equity ratio, indicating prudent leverage levels. The return on equity remains strong, reflecting efficient use of shareholder funds. Equity ratio shows stability, underscoring financial resilience in the industry.

Cash Flow

Operating cash flow is strong, supporting net income effectively, though free cash flow growth has been inconsistent. The company has demonstrated capability in generating free cash flow but should focus on sustaining and improving cash flow generation to support future growth.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	763.75M	829.51M	817.70M	648.68M	419.96M
Gross Profit	478.35M	483.34M	519.61M	384.82M	241.31M
EBITDA	207.69M	245.81M	281.49M	204.72M	93.28M
Net Income	136.88M	170.34M	199.67M	153.08M	61.06M
Balance Sheet
Total Assets	832.02M	799.88M	878.70M	732.68M	574.44M
Cash, Cash Equivalents and Short-Term Investments	27.41M	25.32M	124.94M	99.03M	53.16M
Total Debt	114.41M	65.43M	72.14M	73.14M	73.52M
Total Liabilities	250.48M	256.39M	357.32M	261.70M	200.74M
Stockholders Equity	572.03M	539.39M	520.01M	470.98M	373.70M
Cash Flow
Free Cash Flow	76.06M	58.06M	186.21M	108.50M	7.18M
Operating Cash Flow	138.28M	113.25M	237.60M	149.44M	46.88M
Investing Cash Flow	-81.06M	-52.03M	-57.15M	-40.84M	-39.63M
Financing Cash Flow	-55.36M	-160.84M	-154.54M	-62.73M	-21.52M

Laboratorios Farmaceuticos Rovi Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 54.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:ROVI, the sentiment is Positive. The current price of 54.75 is below the 20-day moving average (MA) of 55.18, above the 50-day MA of 53.34, and below the 200-day MA of 60.24, indicating a neutral trend. The MACD of 0.27 indicates Positive momentum. The RSI at 52.88 is Neutral, neither overbought nor oversold. The STOCH value of 49.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:ROVI.

Laboratorios Farmaceuticos Rovi Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FAE	80 Outperform	€1.41B	12.65	16.04%	1.80%	9.42%	20.43%
ROVI	72 Outperform	€2.78B	20.14	25.24%	1.63%	-1.49%	4.04%
RJF	67 Neutral	€243.38M	22.04	5.11%	1.42%	5.10%	20.61%
Sector *	66 Neutral	€1.73B	33.75	8.73%	1.75%	7.10%	103.68%
ALM	64 Neutral	€2.28B	221.67	0.69%	1.48%	10.20%	―
PHM	59 Neutral	€1.43B	70.19	10.15%	1.01%	8.39%	947.08%

Laboratorios Farmaceuticos Rovi Corporate Events

Rovi Approves Key Resolutions and Re-elects CEO at Shareholders’ Meeting

Laboratorios Farmacéuticos Rovi held its Ordinary General Shareholders’ Meeting, approving key resolutions including the financial accounts for 2024, a dividend distribution, and the re-election of board members. The meeting also authorized the board to acquire own shares, issue bonds, and increase share capital, reflecting strategic moves to enhance corporate governance and financial flexibility. The re-election of Juan López-Belmonte Encina as CEO underscores continuity in leadership, potentially strengthening Rovi’s strategic direction and operational stability.

The most recent analyst rating on (ES:ROVI) stock is a Buy with a EUR104.00 price target. To see the full list of analyst forecasts on Laboratorios Farmaceuticos Rovi stock, see the ES:ROVI Stock Forecast page.

ROVI Secures €36.3 Million for Innovative Drug Development Project

Laboratorios Farmacéuticos ROVI, S.A. has been granted a subsidy of 36.3 million euros from the Center for Technological Development and Innovation (CDTI) for its R&D project, LAISOLID, under the IPCEI Med4Cure initiative. This funding will support the development of new aseptic filling technologies and methodologies to accelerate drug development, with potential applications in tissue regeneration and long-acting injectable formulations, enhancing ROVI’s position in cutting-edge health solutions.

ROVI Announces Upcoming Shareholders’ Meeting and Dividend Proposal

Laboratorios Farmacéuticos ROVI has announced the call for its Ordinary General Shareholders’ Meeting scheduled for June 18, 2025. The meeting will address several key issues, including the proposal to distribute a dividend of 0.9351 euros per share for the 2024 financial year. This announcement reflects ROVI’s commitment to maintaining transparency and engaging with its shareholders, potentially impacting its financial outlook and investor relations.

ROVI Reports First-Quarter 2025 Liquidity Operations

ROVI announced its first-quarter 2025 operations under a liquidity contract with Bestinver SV, S.A., revealing a purchase of 260,242 shares and sale of 256,242 shares, resulting in a final balance of 10,000 shares. The operations reflect a strategic approach to managing liquidity and share value, potentially impacting investor confidence and market positioning.